UrologyNews.net

Urology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Orgovyx, the first oral hormone therapy for treating advanced prostate cancer


The American Cancer Society estimates that in 2020, there will have been more than 190,000 cases of prostate cancer in the U.S.
One of the treatment options for advanced prostate cancer is androgen deprivation therapy, which uses drugs to lower levels of the hormones that help prostate cancer cells grow.
Current FDA-approved treatments of this type are injected or placed as small implants under the skin.

Orgovyx ( Relugolix ) is an orally administered treatment that works by blocking the pituitary gland from making hormones called luteinizing hormone and follicle-stimulating hormone, thereby reducing the amount of testosterone the testicles are able to make.

Orgovyx is indicated for the treatment of adult patients with advanced prostate cancer.

The safety and efficacy of Orgovyx was evaluated in a randomized, open-label trial in men with advanced prostate cancer.
The patients randomly received either Orgovyx once daily or injections of Leuprolide, another hormone-targeting drug, every three months for 48 weeks.
The objective was to determine if Orgovyx achieved and maintained low enough levels of testosterone ( castrate levels ), by day 29 through end of the treatment course.
In the 622 patients who received Orgovyx, the castration rate was 96.7%.

The most common side effects of Orgovyx include: hot flush, increased glucose, increased triglycerides, musculoskeletal pain, decreased hemoglobin, fatigue, constipation, diarrhea and increased levels of certain liver enzymes.

Androgen deprivation therapies such as Orgovyx may affect the heart’s electrical properties or cause electrolyte abnormalities, therefore healthcare providers should consider periodic monitoring of electrocardiograms and electrolytes.

Based on findings in animals and the mechanism of action, Orgovyx can cause fetal harm and loss of pregnancy when administered to a pregnant female; it is advised that males with female partners of reproductive potential use effective contraception during treatment and for two weeks after the last dose of Orgovyx.

Due to the drug’s suppression of the pituitary gonadal system, diagnostic test results of the pituitary gonadotropic and gonadal functions conducted during and after taking Orgovyx may be affected. ( Xagena )

Source: FDA, 2020

XagenaMedicine_2020



Indietro